Abstract Details

Title Inebilizumab for Treatment of NMOSD in a Real-world Cohort: Analysis from the SPHERES Registry

Topic Autoimmune Neurology

Presentation(s) P3 - Poster Session 3 (5:00 PM-6:00 PM)

Poster/Presentation
Number 1-012

Objective This study aimed to describe demographics, disease characteristics, and treatment patterns among patients receiving inebilizumab in a real-world setting.

Background Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune disorder of the central nervous system that affects the optic nerves and spinal cord. Early initiation of maintenance therapy is recommended to reduce NMOSD relapses and prevent disability. Inebilizumab targets CD19+ B cells to reduce the risk of NMOSD relapses.

Design/Methods Patients with NMOSD from the US-based SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry who enrolled from June 2, 2021, to February 28, 2025, and had ever received inebilizumab were included (adults age ≥18 years who were diagnosed with NMOSD according to the 2015 IPND consensus diagnostic criteria). The index visit was defined as the enrollment visit for patients with inebilizumab use prior to enrollment, or the registry visit coinciding with inebilizumab initiation for patients who initiated inebilizumab at or after enrollment.

Results Of 68 patients treated with inebilizumab, 63 (93%) were aquaporin-4 antibody positive. The mean age was 50 years, 93% were female, 38% were White, and 46% were Black/African American. The mean time from diagnosis to index visit was 6 years, but 19% of users were newly diagnosed (within one year of the index visit). Prior to the index visit, 32%, 19%, and 49% of subjects had one, two, or three or more relapses, respectively; the mean number±SD of relapses was 3.2±2.6. Of patients on A-BIOs, inebilizumab was initiated as first-, second-, or third-line therapy in 34% (30/89), 31% (21/67), and 24% (9/37) patients, respectively.

Conclusions This descriptive analysis of real-world NMOSD patients who newly initiated or used inebilizumab provides valuable insights into patient demographic, clinical characteristics, and treatment patterns. While patients were commonly switched to inebilizumab, further analysis is needed to understand long-term real-world outcomes.

Authors/Disclosures
Michael Levy, MD, PhD, FAAN (Massachusetts General Hospital/Harvard Medical School) PRESENTER	Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
Dustin Cavida (Amgen)	Mr. Cavida has received personal compensation for serving as an employee of Amgen. Mr. Cavida has stock in Amgen.
Kristina R. Patterson, MD, PhD (Horizon Therapeutics)	Dr. Patterson has received personal compensation for serving as an employee of Amgen. Dr. Patterson has stock in Amgen.
Jenny Y. Park, PharmD, MS	Dr. Park has received personal compensation for serving as an employee of Amgen Inc.. Dr. Park has or had stock in Amgen Inc..
Rajvi J. Wani, PhD	Dr. Wani has nothing to disclose.
Andrea Meyers, DrPH	Dr. Meyers has received personal compensation for serving as an employee of Amgen. Dr. Meyers has stock in Amgen.
Nicole Middaugh, PhD	Dr. Middaugh has nothing to disclose.
Chien-wen J. Choi	Ms. Choi has received personal compensation for serving as an employee of Thermo Fisher Scientific.
Marie Gurrola	Mrs. Gurrola has nothing to disclose.
Jeffrey L. Bennett, MD, PhD, FAAN (University of Colorado School of Medicine)	Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immpact Bio. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Chugai. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Beigene. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MIAC. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CorEvitas. Dr. Bennett has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vindico. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Touch IME. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Efficient LLC. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Pavich. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Marie Bush. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Marks Gray. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Knight, Nicastro, MacKay. The institution of Dr. Bennett has received research support from Alexion. The institution of Dr. Bennett has received research support from Genentech. Dr. Bennett has received intellectual property interests from a discovery or technology relating to health care. Dr. Bennett has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��